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Introduction
Marijuana is a well-known recreational drug that has
for centuries been prescribed therapeutically in herbal
medicine for the treatment of many disorders, includ-
ing loss of appetite [1]. The identification of the major
active constituent of marijuana, Δ9-THC [2], followed
by the biochemical and pharmacological characteriza-
tion of the cannabinoid receptors [3,4], provided a
solid foundation and opened a new perspectives for the
study of this neurochemical system [5]. Moreover, the
isolation of an endogenous ligand of cannabinoid
receptors - anandamide, description of its synthesis
and metabolic pathways indicated for the existence of
an endocannabinergic system [4,6]. Two cannabinoid
receptor types CB1 and CB2 have been cloned [3]. The
latter appears to be expressed mainly by immune cells,
whereas CB1 receptor is expressed by many central
and peripheral nerve cells, including vagal afferent
neurons [4,7]. 
There is support for the notion that plant-derived
cannabinoids, as well as endogenous and exogenous
cannabinoiods increase food intake [8,9]. Both central
and peripheral sites of action may be involved [10].
Recently it has been indicated that the effect of
endogenous cannabinoids on appetite is mediated by
vagal afferent neurons, suggesting a role in modulating
gut - brain signaling [11,12]. The cannabinoid system
interacts with several peptides involved in the complex
regulation of energy homeostasis such as leptin [13],
orexin [14] and ghrelin [15]. Some authors support the
hypothesis that an increase of ghrelin release in the
peripheral serum is a hunger signal devoted to prevent
energy deficit and to activate meal initiation [16,17]. 
Ghrelin is a hormone recognized as a main endoge-
nous ligand for growth hormone secretagogue recep-
tors (GHS-R), that plays an important role in growth
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hormone release and control of feeding behavior
[16,17,18]. GHS-R1a is highly expressed in the hypo-
thalamus and pituitary gland, consistent with the
actions of ghrelin on the anterior pituitary, as well as
with its influence on the control of appetite, food
intake and energy balance [16,18]. Moreover, recently
the expression of GHS-R1a was described in rat and
human vagal afferent neurons of nodose ganglia [19].
The stomach is the main source of circulating ghre-
lin levels. Ghrelin expression has been localized in
X/A-like cells that account for 20-25% of all endocrine
cells in the mucosa [18]. Ghrelin has also been detect-
ed in many other organs such as the pancreas, bowel,
kidney, placenta, gonads, thyroid, adrenal, lung, pitu-
itary and hypothalamus [20,21,22] and also in many
neoplastic tissues [23]. The potential physiological
role of ghrelin as an autocrine and paracrine factor in
these tissues is still under investigation. The orexi-
genic action of ghrelin is independent of its GH-releas-
ing activity and is mediated by a specific central net-
work of neurones that is also modulated by leptin [24].
According to this hypothesis ghrelin and leptin might
be complementary players of one regulatory system
that has developed to inform the central nervous sys-
tem about the status of energy balance [24,25]. Never-
theless, other data do not support a role for the regula-
tion of circulating ghrelin by leptin levels independ-
ently of changes in adiposity, and suggest that the lep-
tin and ghrelin systems for energy homeostasis func-
tion independently in healthy human subjects [26]. 
From the gastrointestinal tract, ghrelin could regu-
late food intake and energy homeostasis reaching
GHS-R in the hypothalamus through the general circu-
lation [16,18]. Within the hypothalamus, ghrelin binds
mostly on presynaptic terminals of NPY neurones; it
stimulates the activity of arcuate NPY neurones and
mimicks the effect of NPY in the paraventricular
nucleus of the hypothalamus [27]. Thus ghrelin could
represent a novel regulatory circuit controlling
appetite and energy homeostasis by stimulating the
release of orexigenic peptides and neurotransmitters
[25].
In an attempt to evaluate whether orexigenic activ-
ity of cannabinoids is connected with ghrelin release,
the influence of a single ip injection of a stable ana-
logue of anandamide - R-(+)-methanandamide (2.5
mg/kg) and CP 55,940 (0.25 mg/kg), an exogenous
agonist of CB1 receptors, on ghrelin plasma concen-
tration and on ghrelin immunoreactivity in gastric
mucosa in male Wistar rats was investigated.
Materials and methods
Animals. The study was performed on thirty, male Wistar rats
weighing 160 - 170 g. All animals had free access to standard gran-
ulated diet and drinking water. The animals were housed in plastic
cages at 22±1°C and constant humidity, with a 12/12 light/dark
cycle, beginning at 7 am. The rats were randomly divided into 3
groups with 10 animals in each group: rats injected with R-(+)-
methanandamide (2.5 mg/kg) or CP 55,940 (0.25 mg/kg) and a
control group injected with vehicle under the same experimental
conditions. 
Four hours after a single injection of both cannabinoids or a
vehicle, the animals were anaesthetized with pentobarbital sodium
(50 mg/kg b.wt), their abdomen was opened by midline incision
and the blood was taken from the abdominal aorta of each rat for
the measurement of ghrelin serum concentration by radioim-
munoassay (RIA). 
Subsequently, all rats underwent resection of distal part of
stomach. The tissues were fixed in Bouin's fluid and were prepared
to immunohistochemical investigation. 
Determination of ghrelin plasma concentration. The blood,
taken from abdominal aorta of each rat, was collected into
polypropylene tubes without anticoagulant and was incubated in
room temperature until the clot was formed and then centrifuged
(2500 × g for 15 min). The supernatant (serum) was removed and
stored at -20°C until a consequtive analysis. Ghrelin level was
determined by the double-antibody radioimmunoassay technique.
The protocol for radioimmunoassay kit is accessible on the web
site: www.phoenixpeptide.com. 
The immunocytochemical study. The distal part of stomach of
each animal was fixed in Bouin's fluid for one day at 4°C. After
thorough washing in 0.1 M phosphate buffer (pH=7.4) at 4°C, the
tissue was routinely embedded in paraffin, and 5-μm-thick sections
were cut. For blocking of the endogenous peroxidase activity
Peroxidase Blocking Reagent (Dako Poland) was used over 10
minutes. In these studies a specific antibody against ghrelin
(Phoenix) was used. After washing with distilled water and 0.05 M
TRIS-HCl pH=7.4, three times for 5 minutes, the sections were
incubated with the antibody for 1 hour at room temperature. Then,
sections were washed three times in TRIS buffer. Subsequently, the
EnVision method was applied, according to the protocol for iden-
tification of the immunocytochemical reaction [28]. The sections
were counterstained with Mayer's haematoxylin. In the negative
control, the specific antibody was omitted in the staining proce-
dure. Positive control was done for specific tissue recommended
by the producer. The histological preparations were subjected to
analysis, using Olympus B ×50 microscope.
Image analysis. To quantify immunoreactivity of the examined
marker, computerized image analysis was performed. Images were
captured via video link to an Olympus BX50 microscope at 20
objective magnification, so the tissue fully occupied each field, and
was scanned by the computer. Pictures were adjusted for optimal
contrast, fixed at the same brightness levels, and saved in a buffer-
ing system. Staining was analyzed using Olympus Cell D image
analysis computer system as described in details by Postek et al.
[29]. The average optical density was analyzed for cells expressing
ghrelin in both, experimental and control rats. The average optical
density is this method measured values range from 0 to 255 where
0 means black and 255 white color.
Ethical issues. All procedures were performed in compliance with
the European Communities Council Directive of 24 November
1986 (86/609/EEC) and were approved by the Local Ethics Com-
mittee in Bialystok.
Statistics. All values were given as mean ± SD. The Mann-Whit-
ney test was used for testing the differences between both groups
in the intensity of immunocytochemical reactions. The Student-t
test was used for the evaluation of the differences between groups
in ghrelin plasma concentrations. The value p<0.05 was considered
to be significant.
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Four hours after a single ip injection of R-(+)-
methanandamide (2.5 mg/kg) and CP 55,940 (0.25
mg/kg) significant increase of ghrelin plasma concen-
tration (mean values 72.04±11.69 pg/100 µL and
83.7±23.07 pg/100 µL, respectively) as compared to
the mean value in the control rats (46.0±15.04 pg/100
µL) was observed (Fig. 1). 
Results of histological study
Ghrelin immunoreactive (Ghr-IR) cells were distrib-
uted predominantly as single cells, locally in varying
number in the deep zone of the gastric mucosa. Ghr-IR
cells were most abundant in lower parts of gastric
proper glands, while in the neck zone of the glands
they were observed sporadically, both in the control
(Fig. 3) and in the experimental groups of rats (Fig. 4
and 5). These cells were usually round or oval, some-
times spindle-shaped, seldom irregular with short
processes. Their nuclei were usually large, round
structures that occupy the central portions of cells.
While in the X/A like cells of control rats GH-
immunoreactivity appeared as a very strong reaction
(Fig. 3), after a single injection of R-(+)-methanan-
damide (Fig. 4) and CP 55.940 (Fig. 5), GH-
immunoreactivity in gastric mucosa was much weaker.
The average optical density of immunocytochemical
reaction for ghrelin, evaluated by Olympus Soft pro-
gram, was significantly increased in cannabinoids
injected groups of rats in comparison to the control
gastric mucosa (Fig. 2). 
Discussion
The main finding of the present study is the stimulato-
ry effect of a single ip injection of R-(+)-methanan-
damide, a stable analogue of endogenous cannabinoid
- anandamide, and CP 55,940, a potent, egzogenous
agonist of CB1 receptors, on ghrelin secretion from
stomach X/A-like cells. The increase of ghrelin plasma
concentration after application of R-(+)-methanan-
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Fig. 1. Ghrelin plasma concentration evaluated 4 hours after a sin-
gle i.p. injection of R-(+)-Methanandamide (2.5 mg/kg) and CP
55,940 (0.25 mg/kg). Values are means ±SD, *p<0.01 vs control
(Student's test).
Fig. 2. Average optical density of immunohistochemical staining
for ghrelin in X/A-like cells after a single i.p injection of R-(+)-
Methanandamide (2.5 mg/kg) and CP 55,940 (0.25 mg/kg). Values
are means ±SD, **p<0.001 vs control (Mann-Whitney test).
damide and CP 55,940 may partially explain the orex-
igenic action of cannabinoids. 
Our observations are in agreement with an attenua-
tion of ghrelin level after administration of SR141716,
a selective CB1 receptors antagonist, reported by Cani
et al [15]. They indicated that short-term action of a
single injection of SR141716 on appetite is in accor-
dance with the control of ghrelin secretion, a gastroin-
testinal orexigenic peptide, mainly expressed in the
upper part of gastrointestinal tract [15].
The appetite stimulating effect of the Marijuana has
long been known [8]. Plant-derived cannabinoid, Δ9-
THC has been shown to stimulate feeding in a variety
of animal models [8,30]. Δ9-THC-induced feeding was
reversed by the pretreatment with CB1 receptors selec-
tive antagonist, SR141716, that provide a good evi-
dence that this effect is CB1 receptors mediated
[15,31]. The hyperphagic action was observed also fol-
lowing administration of endocannabinoids: anan-
damide and 2-AG [32,33,34]. The increase of food
intake was observed after systemic and central injec-
tion of endocannabinoids and their action was also
reversed by CB1 receptors antagonist [10,15,33]. The
involvement of CB1 receptors in the regulation of
feeding behavior was confirmed by the administration
of the selective CB1 receptor antagonist, SR141716
[15,31]. It has been reported that an acute peripheral
and central administration of SR141716 produced an
inhibition of food intake in laboratory animals [15].
There is support for the notion that in cannabinoids
action regulating feeding behavior central and periph-
eral mechanisms should be considered. The hypothal-
amus and its discrete subregions have long been con-
sidered to play a key role in integrating the multiple
biochemical and behavioral components of feeding
and weight regulation [6]. The involvement of the cen-
tral mechanism in cannabinoids action was confirmed
by the observation that cannabinoid activity in the
hypothalamus varied according to nutritional status
and the expression of feeding behavior [33,35] and
also by the finding that cannabinoids administration
into hypothalamic nuclei induce eating [32,33]. 
However, according to Gomez et al. [12] cannabi-
noids effect on food intake involves predominantly
CB1 receptors localized on capsaicin-sensitive senso-
ry terminals present in gut. This hypothesis is based on
a lack of effect of central administration of cannabi-
noid antagonist, SR141617A on feeding behavior, and
on the ability of capsaicin-induced deafferentation to
prevent changes in feeding elicited by peripheral
administration of cannabinoid drugs [12]. The involve-
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Fig. 3. Light micrograph of gastric mucosa of a control rat. Posi-
tive immunohisochemical reaction for ghrelin is observed in X/A-
like cells (magnification ×400). 
Fig. 4. Light micrograph of gastric mucosa of rat 4 hours after a
singl i.p injection of R-(+)-methanandamide (2.5 mg/kg). The
attenuation of immunohistochemical reaction for ghrelin is
observed in most of X/A-like cells (magnification ×400).
Fig. 5. Light micrograph of gastric mucosa of rat 4 hours after a
single i.p injection of CP 55,940 (0.25 mg/kg). The attenuation of
immunohistochemical reaction for ghrelin is observed in majority
of X/A-like cells (magnification ×400).
ment of peripheral endocannabinoids in the control of
feeding has been supported by observation, that anan-
damide is synthesized within gut tissues, with intestin-
al concentration increasing in 24 hours fasted rats [12].
These findings suggest that stimulation or blockade of
peripheral CB1 receptors may influence central moti-
vational processes, and have been interpreted as indi-
cating a possible role for peripheral anandamide as
"hunger signal".
Several data suggest a relationship between the
cannabinoid system and the gastrointestinal peptides
involved in food intake and apatite regulation [12,15].
Cummings et al. [25] reported an increase of plasma
ghrelin concentration during fasting and rapid
decrease during meal consumption in humans. Recent-
ly Cani et al [15] have shown that an increase of ghre-
lin in fasted rats was abolished by selective CB1 recep-
tors antagonist, SR161417A. This is in agreement with
our observations point to an increase of plasma ghrelin
level after a single ip injection of R-(+)-methanan-
damide and CP 55,940. The localization of CB1 recep-
tors in the mucosal tissue of somach fundus [15], and
ghrelin synthesis occurring in this part of stomach [18]
are in favor of a physiological interaction between
these two systems. Also Konturek et al. [36] have been
recently suggested the interaction between cannabi-
noid and ghrelin signaling pathways in the regulation
of food intake by the brain-gut axis.
It is noteworthy that gastric and intestinal vagal
afferents that express CB1 receptors also express
receptors for the anorexigenic peptide cholecystokinin
(CCK) [11]. Expression of vagal CB1 receptors is
increased by fasting and is diminished by reffeding.
Moreover, CCK, which is released by food and
believed to act as a satiety signal, also decreases CB1
receptors expression in vagal affrent neurons [11].
Thus, it is possible that appetite may be modulated by
interactions between the peptide and cannabinoid sig-
nals originating in the periphery. It has been reported
that CB1 receptor agonist, WIN 55,212-2 inhibited
potassium-evoked CCK release from hippocampal
slides [37]. Moreover, recently the suppression of plas-
ma ghrelin concentration after intravenous CCK-8
infusion was observed [38]. Since CB1 receptor ago-
nists inhibit CCK release, and CCK suppresses ghrelin
secretion, it seems to be possible that observed in the
present study the enhancement of ghrelin secretion
after cannabinoids injection was evoked by the inhibi-
tion of CCK suppression on ghrelin release (disin-
hibitory effect). This possibility is in accordance with
the observation based on immunhistochemical study
performed by Burdyga et al. [19], directed at GHS-
R1a of the ghrelin receptors, that revealed the expres-
sion of these receptors in over 75% of neurons in
nodose ganglia expressing CCK-1 receptors. The latter
authors suggest that the actions of CCK and ghrelin are
mediated by a common population of vagal afferent
neurons.
Although, there is an increasing evidence for a
peripheral role of the cannabinoid system in food-con-
sumption behavior, the molecular mechanism of dif-
ferent cannabinoid-ralated molecules action on food
intake through their influence on gastrointestinal tract
remains to be fully elucidated. 
The present study suggests that the modulation of
the secretion of gastrointestinal orexigenic peptides
such as ghrelin, by the peripheral cannabinoid system,
mainly expressed in the upper part of the gastrointesti-
nal tract, may participate in food regulation. 
In conclusion, our study indicates that stimulation
of appetite exerted by cannabinoids might be connect-
ed with an increase of ghrelin secretion from gastric
X/A-like cells.
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